TL;DR
Get oils, diffusers and self-care delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The Washington Sun reported that White House Chief of Staff Susie Wiles urged Attorney General Todd Blanche to hold off on actions that could restrict abortion-pill access until after the midterm elections. The White House called the account “completely false,” and no public directive confirming the reported delay has been disclosed. The report comes as the administration reviews mifepristone rules and Blanche has signaled interest in revisiting the federal government’s interpretation of the Comstock Act.
The White House denied a report that Chief of Staff Susie Wiles told the Justice Department to hold off on measures restricting abortion-pill access until after the midterm elections. The Washington Sun, citing senior administration officials and anti-abortion advocates, reported that Wiles warned Attorney General Todd Blanche that an aggressive move could hurt Republicans politically; no public directive confirming the account has been disclosed.
The Sun’s report describes an alleged effort to delay action rather than abandon it. One senior administration official told the outlet, “No one wants us taking any real action before the midterms,” characterizing a message the official said White House staff had conveyed to the Justice Department. The White House said the report was “completely false” and denied that the reported meetings took place.
Some anti-abortion advocates told the Sun they believe restrictions could be pursued after the election. One activist said, “Once the midterms are over and it’s truly lame-duck time, we’ve heard the gloves will be off.” That is an activist’s account of what they have heard, not confirmation of a White House decision or a formal DOJ plan.
The report comes amid several policy developments involving mifepristone, the medication used in most medication abortions. The DOJ has asked courts to pause state cases challenging FDA policies that allow prescriptions through telehealth and delivery by mail, but the source report says the department has not defended those policies on their merits. Health and Human Services Secretary Robert F. Kennedy Jr. has also spearheaded an FDA safety review that could lead to tighter rules, while Blanche has said he would revisit the department’s position on the Comstock Act.
Election Timing and Abortion Access
The reported timing matters because a delay could leave existing federal policies on telehealth and mailed mifepristone in place through the election period, while postponing a politically contentious fight. If restrictions were later pursued, they could affect access beyond states that have already imposed abortion bans, depending on the legal route and the scope of any changes.
The political stakes are part of the report, not proof of the administration’s motive. Common Dreams cites polling showing six in 10 Americans support abortion being legal in all or most cases and 68% oppose a nationwide ban on medication abortion. The figures help explain why an election-year policy shift could draw voter attention, but they do not establish that officials made the alleged decision.
For patients and providers, the immediate distinction is between existing rules and possible future action. The reported pause would not itself change access; any restrictions would require identifiable legal or regulatory steps. The account also underscores that court cases and federal agency reviews may shape access independently of any election-related timetable.
As an affiliate, we earn on qualifying purchases.
The Legal Routes Under Review
Mifepristone is used in medication abortion, which accounts for nearly two-thirds of abortions in the United States, according to the source report. Since the Supreme Court’s 2022 Dobbs v. Jackson Women’s Health Organization decision overturned the national constitutional right to abortion, disputes over access have increasingly played out through state laws, federal court cases and federal agency policy.
One potential route discussed in the report is the 1873 Comstock Act, a federal law restricting the mailing of items deemed obscene or related to abortion. In 2022, the Biden administration’s DOJ issued a legal opinion saying the law does not prohibit mailing abortion drugs when the sender does not intend them to be used unlawfully. Blanche said at his confirmation hearing that he would revisit that opinion and use “every lawful action available” to enforce the law.
That possible interpretation is contested and has not been established in court as a nationwide abortion ban. The source report quotes Amy Littlefield of The Nation describing Comstock as a possible “nuclear option,” and notes that abortion opponents have urged a broad reading. These are arguments about potential legal consequences, not evidence that the DOJ has adopted such an interpretation.
““Completely false.””
— White House, responding to the Washington Sun report
No Public Order or Timeline
The key claim—that Wiles intervened to delay DOJ action—rests on sources quoted by the Washington Sun and is explicitly denied by the White House. The supplied reporting does not include a written instruction, a public confirmation from Blanche, or an identified official policy setting a post-midterm date.
It is also unclear what action, if any, the DOJ may take on the Comstock Act opinion, whether the department plans to change its position in active court cases, or what conclusions the FDA review of mifepristone will reach. The report describes advocates’ expectations and officials’ alleged political concerns; neither establishes a final decision. Any future change would depend on the specific agency action, legal process and potential court challenges.
Court Cases and FDA Review
The next developments to watch are the DOJ’s filings in state lawsuits over FDA rules, any public move to revise the 2022 Comstock Act opinion, and findings from the FDA’s mifepristone review. The source material gives no announced timetable for those steps and does not say the department has formally agreed to wait until after the election.
Until an agency action, court ruling or formal policy statement is made public, the reported delay remains disputed. The White House’s denial and any response from Blanche or the DOJ could clarify whether the account reflects an actual instruction, an informal discussion, or advocates’ interpretation of the administration’s intentions.
Key Questions
What did the report say the White House asked the DOJ to do?
The Washington Sun reported that Chief of Staff Susie Wiles urged the DOJ to avoid taking major steps to restrict abortion-pill access until after the midterm elections. The White House denied that the reported meetings took place.
Has the DOJ confirmed a decision to wait until after the midterms?
No formal DOJ decision or written instruction is included in the source material. The claim comes from sources quoted by the Sun, and the White House called the report “completely false.”
What is the Comstock Act’s role in the dispute?
The 1873 law restricts the mailing of certain materials. The source report says Blanche has indicated he would revisit a 2022 DOJ opinion that limited how the law applies to abortion drugs. Whether the law could support broader restrictions is disputed and has not been resolved by a court in the way advocates described.
Could abortion-pill access change before the election?
The report says officials and advocates anticipate a delay, but it does not establish that one is in effect. Existing court cases and the FDA review could produce developments; no specific action or date is confirmed in the supplied material.
Source: fediverse
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
